Importantly, this improvement did not come with a higher risk of major bleeding, a common concern with blood-thinning drugs. The findings were presented at the European Society of Cardiology Congress in Madrid and published simultaneously in The Lancet.

Why Aspirin Was the Default Choice

For many years, doctors have routinely prescribed low-dose aspirin to patients with coronary artery disease—the most common type of heart disease—to help lower the risk of blood clots. Aspirin makes blood less likely to clot, lowering the chances of blockages in narrowed arteries. This approach has been central to preventing repeat heart attacks and strokes.

Despite its popularity, aspirin has always carried a risk of gastrointestinal bleeding and, in some cases, has not been as effective as hoped over the long term.

Clopidogrel, which has been in use since the late 1990s, works differently by blocking a platelet receptor called P2Y₁₂. It has usually been given alongside aspirin as part of dual antiplatelet therapy or prescribed to patients who cannot tolerate aspirin. Until now, it was not considered a superior option for long-term use on its own.

What the Study Found

The new analysis combined data from seven clinical trials that followed nearly 29,000 patients with coronary artery disease. These patients came from different backgrounds and included those who had undergone stent placement or had experienced acute coronary syndromes.

Across this broad group, clopidogrel consistently performed better than aspirin. Patients taking clopidogrel experienced fewer major cardiovascular and cerebrovascular events, while rates of bleeding were essentially the same as those in the aspirin group.

Patients predicted to have a weaker response to clopidogrel because of genetic or clinical factors still showed better outcomes than those taking aspirin.

Evidence from Other Clinical Trials

The results align with findings from earlier studies. The HOST-EXAM trial, which followed more than 5,000 patients in South Korea after stent placement, reported fewer heart attacks, strokes, and bleeding complications in patients treated with clopidogrel instead of aspirin over almost six years.

Another trial, SMART-CHOICE 3, found that clopidogrel reduced the combined risk of death, heart attack, and stroke in high-risk patients compared to aspirin, again without raising bleeding risk. Together, these studies strengthen the case for clopidogrel as a safer and more effective long-term treatment option.

Implications for Patients and Guidelines

The latest findings indicate that clopidogrel may emerge as the favored option for long-term prevention of heart attacks and strokes in people with coronary artery disease. Experts believe the drug’s generic availability, affordability, and proven effectiveness make it suitable for widespread use. However, some considerations remain.

Clopidogrel is a prescription-only drug, unlike aspirin, which can be bought over the counter. Genetic variations in how patients metabolize clopidogrel may also influence its effectiveness in some cases, although the current analysis indicates benefits are still widespread.

Certain acid-reducing medications, such as omeprazole, may interfere with clopidogrel’s action, which means doctors will need to guide patients carefully on safe combinations.

Researchers emphasize that further studies on cost-effectiveness and outcomes in more diverse populations are needed before treatment guidelines are updated worldwide. Still, the data strongly indicate that clopidogrel provides superior long-term protection without added risks.

[Source]

The post Clopidogrel Outperforms Aspirin for Long-Term Heart Protection, Study Shows appeared first on Medical Journal Daily.

The study, published in Nature Aging, found that FTL1 builds up in the hippocampus, the brain’s memory center, as mice get older. Too much of this protein disrupts brain function. Older mice with elevated FTL1 performed poorly on memory tasks. To confirm the link, scientists boosted FTL1 in younger mice.

To confirm the link, scientists boosted FTL1 in younger mice. These healthy mice quickly developed memory problems similar to older ones. But when scientists lowered FTL1 levels in aging mice, something remarkable happened: their memory improved to the level of much younger mice.

How FTL1 Affects the Brain

FTL1 helps store iron inside cells, but when it builds up in the brain, it disrupts how neurons generate and use energy. Neurons need energy to build and maintain connections, which are the pathways for learning and memory.

When FTL1 levels rise, neurons lose power. They cannot store information as effectively, leading to forgetfulness. Scientists also observed that older mice with high FTL1 had fewer connections between brain cells.

The team used advanced tools, including viruses and genetic methods, to change FTL1 levels. They then put mice through memory and learning challenges, such as solving mazes and recognizing objects. After reducing FTL1, older mice performed almost as well as young mice, proving that brain function could be restored.

The research also tested metabolism. Researchers discovered that when FTL1 levels rise, neurons struggle to produce enough energy. When they added NADH, a compound that helps with cell energy, memory problems improved. This suggests that targeting brain energy systems could be another way to help with memory loss reversal.

What This Means for Humans

While the results are exciting, the research is still at an early stage. The experiments were done only in male mice, and the human brain is far more complex. A treatment that works in mice may not work the same way in people.

Currently, there are no safe drugs that directly reduce FTL1 in humans. The methods used in the study involved genetic tools, not medicines. Researchers warn that it could take years before this discovery leads to new therapies.

Still, the findings are important because they focus on normal, age-related memory decline, not just diseases like Alzheimer’s. Almost everyone experiences some memory loss with age. By targeting FTL1, scientists may one day find a way to help a much larger group of people.

In the United States, between six and 12 million people over 65 live with mild cognitive impairment, a condition that often leads to dementia. About one-third of them develop Alzheimer’s within five years. For these individuals, new options for memory loss reversal could make a huge difference.

A New Direction in Brain Research

For decades, dementia research has centered on proteins like beta-amyloid and tau, which form clumps and tangles in the brain. The UCSF study adds a new angle by showing that iron-related proteins and energy systems may also be key to memory decline.

By focusing on FTL1, scientists are opening doors to treatments that could help almost everyone as they grow older—not just those with Alzheimer’s disease.

[Source]

The post Scientists Find Way to Reverse Memory Loss in Mice appeared first on Medical Journal Daily.

This research not only offers a new therapeutic avenue but also sheds light on the shared biological mechanisms that may link autism and epilepsy.

The Study

The study focused on the reticular thalamic nucleus (RT), a part of the brain responsible for processing sensory information. The researchers used mouse models of autism spectrum disorder (ASD), which were genetically modified with mutations in the CNTNAP2 gene, a gene strongly associated with autism.

These mice exhibited classic autism-like behaviors, including repetitive grooming, social withdrawal, hyperactivity, and an increased susceptibility to seizures. The scientists discovered that the neurons in their RT were overactive, a phenomenon linked to strong currents in what are known as T-type calcium channels.

The team then introduced Z944, also known as ulixacaltamide, a drug being studied as a potential treatment for seizure disorders. Z944 is a T-type calcium channel antagonist, meaning it works by blocking these specific currents.

The results were nothing short of remarkable. After administering just one dose of Z944, the mice showed a significant reversal of their autistic behaviors. Their repetitive grooming decreased, they became more socially interactive, and their hyperactivity was reduced.

The drug appeared to “quiet” the overactive RT region, leading to a profound change in their behavior. This finding was further validated when the researchers genetically modified the mice to have increased activity in the RT, causing the autistic behaviors to return.

This suggests that Z944’s ability to suppress this specific brain region is the key to its therapeutic effect.

The Overlap Between Autism and Epilepsy

The findings of this study provide crucial evidence for a long-suspected connection between autism and epilepsy. Autistic individuals are up to 30 times more likely to develop epilepsy than the general population. This high comorbidity has led experts to believe that the two conditions may share underlying biological mechanisms, and this new research strongly supports that theory.

The study suggests that the same overactive neural circuits and channels in the RT that contribute to autistic symptoms may also be a factor in seizure activity. This potential overlap not only explains why the conditions often coexist but also highlights a promising new target for treatment that could address both simultaneously.

While the prospect of a single-dose treatment is exciting, the researchers are quick to emphasize that these findings are still preliminary and based on animal models.

It remains unclear how these results will translate to humans. However, the study provides a critical framework for future research. The scientists note that the next steps should focus on understanding how the RT’s influence on the broader brain circuitry affects the full spectrum of ASD behaviors.

This knowledge could pave the way for highly precise, circuit-specific interventions tailored to the needs of individuals with autism. As Z944 continues its clinical trials for epilepsy, its potential as a dual-purpose drug for both epilepsy and autism remains a captivating possibility that could fundamentally change the lives of millions.

[Source]

The post New Seizure Drug Shows Promise in Reversing Autism Symptoms in Mice appeared first on Medical Journal Daily.

The illness is defined by an overwhelming and unrelenting fatigue that does not improve with rest, often coupled with pain, cognitive difficulties, and post-exertional malaise—a sudden worsening of symptoms after even small amounts of physical or mental activity. Despite its impact, there has been no diagnostic test, no clear biological explanation, and no proven cure.

Now, a major genetic study is beginning to change that narrative. The DecodeME project, launched in 2022 and led by scientists at the University of Edinburgh with support from patient advocacy groups, has provided the strongest evidence yet that biology—rather than behavior or psychology—plays a central role in ME/CFS.

Eight Genetic Signals—What They Reveal

Researchers examined DNA samples from more than 15,000 people with the illness and compared them to over 250,000 individuals without it. What they found was striking: eight regions of DNA where genetic differences were far more common among patients than in the general population.

These differences, often referred to as “genetic signals,” appear to cluster around two key biological systems—the immune system and the nervous system. Some of the genes identified are known to influence how the body responds to infection, a finding that echoes the experiences of many patients who report that their illness began after a viral or bacterial illness.

Others are linked to pathways involved in pain regulation, which may help explain why chronic pain is such a common feature of the condition.

Importantly, the study also showed that these genetic differences are not associated with psychiatric conditions such as depression or anxiety, helping to counter the long-standing misconception that ME/CFS is primarily psychological in nature.

Implications

The implications of these findings are significant, though researchers caution that they are only the beginning. The genetic associations discovered by DecodeME cannot yet be used to diagnose the illness, nor do they immediately translate into treatment.

What they do provide, however, is a roadmap for future research—clues that point scientists toward the biological processes most likely driving ME/CFS. By focusing on immune and neurological pathways, researchers may be able to develop targeted studies and, eventually, new therapies that address the underlying mechanisms rather than just the symptoms.

For patients, the study represents more than just scientific progress—it is also a moment of validation. ME/CFS has historically been misunderstood, with many sufferers facing disbelief from clinicians, employers, and even friends or family. The discovery that the illness is written, at least in part, into the genome underscores that it is not imagined, but rooted in biology. As Professor Chris Ponting, who leads the DecodeME study, has noted, these results mark a turning point in how the illness is perceived within the medical and research communities.

Future Directions

The DecodeME team is continuing its work, expanding the study to include participants from more diverse backgrounds and conducting deeper analyses of genetic variation. They have also made their dataset available to scientists around the world in the hope that collaboration will accelerate discoveries.

While it may take years to translate these findings into practical treatments, the momentum is now firmly on the side of progress. For a patient community that has long waited for recognition and solutions, this study offers both a clearer biological foundation and a renewed sense of hope.

[Source]

The post Major Study Reveals Genetic Roots of Chronic Fatigue Syndrome appeared first on Medical Journal Daily.

What is Vein of Galen Malformation?

In a person with Vein of Galen malformation (VOGM), arteries connect directly to veins deep in the brain without the normal network of capillaries in between. Without this slowing mechanism, blood rushes at high pressure into the brain’s deep veins, placing strain on the heart and affecting brain function.

The condition can cause a range of serious problems, including heart failure, a build-up of fluid in the brain (hydrocephalus), seizures, developmental delays, and sometimes bleeding within the brain. If left untreated, it carries a very high risk of death—some estimates put mortality at more than three-quarters of cases. Even when treated, the risks remain significant.

Most children diagnosed with VOGM undergo a less invasive treatment known as endovascular embolization. In this procedure, doctors insert a catheter—typically through the groin—and navigate it through the blood vessels until it reaches the abnormal connection in the brain. Special materials are then placed to block the abnormal connections. This technique has transformed survival rates and outcomes for many patients.

A Different Kind of Challenge

For Conor O’Rourke, a three-year-old from Liverpool, standard treatment was not enough. His VOGM was first picked up during a routine check, when a consultant spotted that the shape of his head seemed unusual. Further investigation confirmed the diagnosis—but his case would prove far from straightforward.

But surgeons discovered a major complication—his jugular veins were blocked. This prevented them from reaching the malformation via the normal route, leaving the swelling unchecked and causing damage to his brainstem and spinal cord.

Faced with no viable alternative, neurosurgeon Conor Mallucci and his team at Alder Hey Children’s Hospital designed a new approach. In March, they carried out what is believed to be the world’s first direct open-skull operation for this type of VOGM. By accessing the malformation directly through the skull, they were able to treat it successfully.

Conor’s recovery was described as remarkable. According to his surgical team, he is now “99 per cent cured” and doing well.

Why This Breakthrough Matters

This breakthrough offers hope for children with high-risk cases of Vein of Galen malformation, particularly those whose anatomy or blocked vessels make traditional embolization impossible. By creating an entirely new treatment pathway, it addresses situations where no viable options previously existed and survival chances were low.

Conor’s case also highlights the critical role of early detection—his diagnosis was made possible when an attentive doctor noticed subtle signs during a routine check-up, allowing intervention before further damage occurred.

Finally, it underlines the value of specialist expertise, as Alder Hey is one of only two centers in the UK equipped to carry out such complex pediatric neurosurgery.

Around the world, researchers are also looking at treating VOGM before a baby is born.

In the United States, specialists recently performed the first in-utero embolization, using ultrasound to guide a microcatheter into a fetus’s brain and place small coils to slow blood flow. The baby was delivered with improved heart function and no signs of brain injury. While still experimental, such procedures hint at the possibility of preventing damage before it starts.

The Road Ahead

Even with the best treatment, VOGM is a lifelong condition that requires careful follow-up. Children may need ongoing input from neurosurgeons, cardiologists, neurologists, and developmental specialists to monitor growth and learning.

Historical data from Great Ormond Street Hospital between 2003 and 2008 found that among children who survived treatment, 39% developed normally, 21% had mild developmental delays, and 18% had more significant challenges. These figures show why surgical advances like the one at Alder Hey could make such a difference—not just in saving lives, but in improving how those lives are lived.

[Source: 1,2]

The post World-First Surgery at Alder Hey Saves Toddler from Rare Vein of Galen Malformation appeared first on Medical Journal Daily.

Rewriting Gene Activity in the Diseased Brain

Alzheimer’s disease disrupts how genes operate in brain cells. To understand this better, scientists first mapped the patterns of gene activity in individual neurons and support cells (called glia) from brains affected by the disease. This process, known as gene expression profiling, shows which genes are active or dormant. The researchers then searched for drugs that could flip those patterns back toward normal.

They turned to a large public database called the Connectivity Map, which catalogs how thousands of drugs affect gene activity in human cells. Out of 1,300 drugs, just 10 reversed Alzheimer’s-linked gene patterns across different brain cell types, and only five were already approved by the U.S. Food and Drug Administration.

Using medical records from over 1.4 million patients across California’s university hospitals, the researchers looked for any real-world signs that those drugs might help prevent Alzheimer’s. The records showed that people who had taken some of these medications, mostly for cancer, appeared less likely to develop the disease later on.

Targeting Two Cell Types with a Two-Drug Combo

From this shortlist, the team selected two drugs: letrozole, typically used to treat breast cancer, and irinotecan, used against colon and lung cancers. They believed each drug would target a different cell type — letrozole for neurons and irinotecan for glia — like a two-part key unlocking different doors in the brain.

When given to mice with advanced Alzheimer’s-like symptoms, the drug duo had striking effects. It stopped further damage, reduced toxic protein buildup, and even restored the animals’ ability to remember how to navigate mazes. Memory, in this case, was not just protected, it was brought back from the edge.

The researchers compare the process to rewiring a city after a blackout, where different crews work on separate grid sections, but the lights only come back when efforts are synchronized. Similarly, targeting both neurons and glia may be the missing link that single-drug strategies have overlooked.

A Possible Turning Point for Alzheimer’s Treatment

“This study opens a new door using drugs we already have,” said lead researcher Yadong Huang. His team emphasizes that although results in mice are promising, human trials are essential to confirm safety and effectiveness.

Letrozole and irinotecan, though widely used in cancer treatment, can come with serious side effects. If repurposed for Alzheimer’s, their doses and delivery methods will likely need major adjustments. The upside? Since the drugs are already approved, clinical trials could begin sooner than if researchers had to start from scratch.

With over 55 million people living with Alzheimer’s worldwide and that number set to double in the next two decades.

As co-author Marina Sirota puts it, “When two completely different kinds of data — from cells and from real patients — lead to the same drug, and it works in a model of the disease, we may finally be onto something.”

[Source]

The post Two Cancer Drugs Show Surprising Potential Against Alzheimer’s in Early Tests appeared first on Medical Journal Daily.

Found in Thousands of Low-Calorie Products

Erythritol appears in everything from protein bars to flavored water, offering about 80% the sweetness of sugar without the calories or spikes in insulin. Its widespread use has grown with the popularity of low-sugar and diabetic-friendly diets.

But this sweetener, often labeled as natural due to its presence in some fruits and fermentation processes, may carry hidden risks.

The new study examined how erythritol affects the blood-brain barrier—the brain’s critical filtering system. Researchers exposed brain blood vessel cells to amounts of erythritol comparable to what’s found in a single sugar-free beverage. They observed a damaging cascade: increased oxidative stress, reduced antioxidant activity, and even cell death.

These changes also disrupted the delicate balance between two key molecules: nitric oxide and endothelin-1. Nitric oxide relaxes blood vessels, promoting healthy blood flow, while endothelin-1 causes them to constrict. Erythritol lowered levels of nitric oxide while boosting endothelin-1, causing blood vessels to stay narrowed. This narrowing can limit the brain’s access to oxygen and nutrients, increasing the risk of ischaemic stroke.

It also weakened the cells’ natural capacity to break down blood clots. Normally, they release a compound called tissue plasminogen activator (t-PA) to break down clots. But erythritol suppressed this mechanism, potentially leaving clots to accumulate and increase the risk of stroke.

Echoes of Earlier Human Studies

The laboratory results align with previous human studies. One 2023 investigation that tracked over 4,000 individuals across the US and Europe found that those with elevated erythritol levels in their blood had nearly double the risk of experiencing a heart attack or stroke within three years.

Another study showed that 30 grams of erythritol—a typical serving in sugar-free ice cream—can make blood platelets more likely to clump, setting the stage for clot formation.

Erythritol is often promoted as a “natural” alternative to artificial sweeteners like aspartame or sucralose, and its chemistry makes it easier to substitute for sugar in recipes. Because it’s technically a sugar alcohol and produced in small amounts by the body, it has largely avoided the negative attention directed at other synthetic sweeteners.

However, experts warn that its natural origin does not guarantee safety. The U.S. Food and Drug Administration and European Food Safety Authority have approved it for consumption, but the new data suggest long-term effects may not be fully understood.

What This Means for Consumers

Researchers emphasize that their experiments were conducted on isolated cells in laboratory conditions. Human bodies are more complex, and more research—especially studies involving whole-body responses or advanced vascular models—is needed to draw final conclusions.

Still, scientists advise consumers to read labels and be mindful of erythritol intake, especially if they consume multiple servings of sugar-free products daily. Given the links to vascular dysfunction and stroke risk, moderation may be a wise approach.

[Source]

The post A Common Sugar Substitute May Damage Brain’s Protective Barrier, Raise Stroke Risk, New Research Warns appeared first on Medical Journal Daily.

A General Immune Boost Instead of a Specific Target

Most cancer immunotherapies rely on identifying and attacking neoepitopes—proteins that arise from mutations specific to a patient’s tumor. This approach works best in cancers with high mutation loads, such as melanoma, but has limited success in tumors with low mutational burden. A study published in Nature Biomedical Engineering and conducted by scientists at the University of Florida challenges that model.

In their experiments, researchers used an experimental mRNA vaccine delivered via lipid nanoparticles, similar to the technology used in COVID-19 vaccines. But instead of encoding a viral protein, this vaccine instructs the immune system to produce proteins that activate an immune response.

One of these proteins, PD-L1, is commonly found on cancer cells and helps them evade immune detection. By artificially inducing PD-L1 expression in tumors, the vaccine made the cancer cells more visible to the immune system, improving the effects of immune checkpoint inhibitors.

Making Resistant Tumors Respond to Treatment

In mouse models of melanoma, the mRNA vaccine cleared drug-resistant tumors and triggered “antigenic spreading”—a process where the immune system begins to recognize and attack multiple tumor-related antigens. In some cases, the vaccine worked even without additional treatments. It was also tested in models of brain, skin, and bone cancers with similarly promising results.

Researchers demonstrated that tumors resistant to checkpoint inhibitors lacked these early immune signals, but became sensitive when treated with RNA-loaded lipid particles that boosted interferon activity. This led to a broader immune reaction, enabling previously unresponsive tumors to respond to immunotherapy.

Together, these results highlight a new paradigm in cancer treatment: instead of customizing a vaccine to match each patient’s unique tumor profile, it may be possible to create a general-purpose vaccine that teaches the immune system to react aggressively to cancer, regardless of the tumor’s specifics.

Laying the Groundwork for an Off-the-Shelf Cancer Vaccine

Dr. Elias Sayour, a pediatric oncologist at the University of Florida and lead investigator on the study, described the results as “a proof of concept” that such a vaccine could eventually become an off-the-shelf solution. Co-author Dr. Duane Mitchell added that this approach may pave the way for more accessible and broadly applicable cancer treatments.

While these findings are based on animal studies, they offer a strong foundation for clinical research. If the vaccine proves effective in humans, it could significantly improve cancer immunotherapy, especially for patients with tumors that previously showed little to no response.

The research not only expands the potential use of mRNA technology beyond infectious disease but also underscores the power of immune system priming. As development continues, a universal cancer vaccine may soon become a powerful tool in the fight against one of the world’s most complex diseases.

[Source]

The post Universal Cancer Vaccine Shows Promise in Boosting Immunotherapy Response appeared first on Medical Journal Daily.

1. Green Tea (and Black Tea):

Rich in catechins and gallic acid, green and black teas can block xanthine oxidase, thereby reducing uric acid production. In fact, gallic acid in tea has one of the strongest XO-inhibiting effects, outperforming even other tea polyphenols. Enjoy 2–3 cups of unsweetened green or black tea daily (hot or iced). For example, have a cup in the morning instead of sugary beverages, or use cooled green tea as a base for smoothies. This provides a steady intake of XO-inhibiting compounds and can be a simple, soothing addition to your routine.

2. Coffee:

Moderate coffee consumption is associated with lower uric acid levels. Coffee contains chlorogenic acid (a polyphenol) and low doses of caffeine, which together inhibit xanthine oxidase and increase uric acid excretion. Essentially, chlorogenic acid in coffee acts similarly to allopurinol by occupying XO’s active site, thus preventing the formation of uric acid. If you tolerate caffeine, one or two cups of coffee a day (preferably black or low-sugar) can be beneficial. For instance, you might replace a mid-morning snack with a cup of black coffee or have it with breakfast. The diuretic effect of coffee’s polyphenols also helps flush out uric acid, but be sure to stay hydrated.

3. Tart Cherries (and Cherry Juice):

Tart cherries are famed as a home remedy for gout – and for good reason. They are high in anthocyanins, which not only have anti-inflammatory effects but may also inhibit xanthine oxidase. Studies have observed that regular tart cherry intake is linked to reduced serum uric acid and fewer gout flares. Cherry compounds can increase urate excretion and even showed a synergistic effect with allopurinol in research. You can drink an 8-ounce glass of 100% tart cherry juice daily (for example, in the morning or post-dinner), or eat a handful of fresh or frozen tart cherries as a snack. Alternatively, concentrated tart cherry capsules are available online. This sweet-tart fruit is an easy dessert swap that may help control uric acid levels.

4. Apples and Onions (Quercetin-Rich Foods):

Apples (especially with skins) and onions are high in quercetin, a flavonoid that inhibits xanthine oxidoreductase – the final step of uric acid synthesis. Quercetin has been shown in human studies to lower blood uric acid; for example, 500 mg of quercetin daily (equivalent to the quercetin in about one large red onion or several apples) significantly reduced serum urate in pre-hyperuricemic men. To get quercetin through diet, try eating an apple a day (as a snack or chopped into oatmeal) and use onions generously in cooking (soups, salads, stir-fries, etc.). Red onions, in particular, are very high in quercetin. By incorporating these foods regularly, you’ll get a consistent dose of this natural XO inhibitor alongside vitamins and fiber.

5. Celery and Celery Seeds:

Celery has long been used as a folk remedy for gout. Luteolin, a flavonoid abundant in celery (particularly in celery seeds), is a potent xanthine oxidase inhibitor. Research confirms that celery seed extracts can lower uric acid and block XO activity in animal models of hyperuricemia. You can integrate this by sprinkling celery seeds (about ¼ teaspoon) into soups, stews, or even smoothies – they have a mild, earthy flavor. Alternatively, steep celery seeds in hot water to make a tea, or take a celery seed extract supplement (readily available online). Eating fresh celery stalks is healthy too (as snacks or in salads), though the seeds have a higher concentration of luteolin. For example, you might add a pinch of ground celery seed to a vegetable juice or morning eggs for an extra anti-gout boost.

6. Ginger:

Common ginger root contains bioactive compounds (gingerols and shogaols) that have XO-inhibiting and anti-inflammatory properties. Notably, 6-gingerol in ginger has been shown to inhibit xanthine oxidase, thus interfering with the formation of uric acid. While ginger is often used to ease nausea or arthritis, it may also help keep uric acid in check by reducing production and oxidative stress. You can easily use fresh ginger in your diet: grate it into stir-fries, steep slices in hot water for a soothing ginger tea, or add it to smoothies and marinades. Even ginger powder can be used in curries or sprinkled on roasted vegetables. For instance, try drinking a cup of ginger tea after meals – not only is it calming for digestion, but it also provides those XO-inhibiting compounds in a warm, caffeine-free beverage.

7. Turmeric:

Turmeric (the golden-yellow spice) contains curcumin, which emerging research suggests can inhibit xanthine oxidase and also act as a uricosuric, helping the kidneys excrete uric acid. This dual action means turmeric might reduce uric acid both by producing less of it and by getting rid of it faster. In one clinical trial, curcumin supplements lowered serum urate about 7% (though results were comparable to placebo, indicating more research is needed). Regardless, turmeric’s anti-inflammatory benefits are well known and can be useful if you have any gouty joint pain. To incorporate turmeric, add ½–1 teaspoon of turmeric powder to your cooking daily – for example, stir it into soups, stews, or rice, or use it to make “golden milk” (turmeric latte) with milk/non-dairy milk and a pinch of black pepper (which boosts curcumin absorption). You can also take curcumin capsules available online for a concentrated dose. Be consistent; using a bit of turmeric every day – such as in scrambled eggs or a smoothie – can provide a steady supply of curcumin. (Tip: combine with black pepper and a healthy fat like olive oil when cooking, to enhance absorption of curcumin.)

Practical Tips: Aim to incorporate several of these options in your daily diet for a combined effect. For instance, you might start your day with a cup of green tea or coffee, enjoy an apple as a snack, use onions and ginger in your lunch/dinner recipe, and have a glass of tart cherry juice in the evening. Sprinkle in turmeric and celery seeds while cooking your meals. By using these natural xanthine oxidase inhibitors regularly, you can gradually lower uric acid levels.

Always remember to monitor your levels and consult with a healthcare provider for personalized guidance, but these additions are safe, accessible steps that leverage nature’s own XO inhibitors.

The post 7 Natural Dietary Xanthine Oxidase Inhibitors to Reduce Uric Acid appeared first on Medical Journal Daily.

Dental Pulp Cells Can Repair Tissues Beyond the Mouth

Scientists around the world are culturing and testing dental pulp cells in the lab. At CSIRO’s Stem Cell Centre in Australia, for instance, researchers examine cultured stem‑cell samples under high‑resolution microscopes.

In the lab, DPSCs self‑renew and proliferate rapidly. Studies show that when given the right signals, DPSCs will lay down collagen and calcium to form bone or cartilage matrix and even beat and contract like muscle.

Compared with bone‑marrow stem cells, DPSCs often build mineralized (bone) tissue more quickly. In engineered joint grafts they can produce cartilage tissue in vitro. In one animal study, combining human dental pulp cells with a scaffold led to significantly more new bone growth than a scaffold alone.

Such findings give hope that wisdom‑tooth cells could one day aid in healing fractures, repairing jawbones after tumor surgery, or rebuilding degenerated cartilage in arthritic joints. Each year millions of wisdom teeth are removed and usually discarded. In the United States alone an estimated ten million molars are extracted annually.

Tooth Banking and the Future of Personalized Medicine

A growing number of biotech startups and dental clinics now offer “tooth banking” – preserving a patient’s pulp cells for possible future use. The process of collecting dental pulp stem cells begins immediately after the tooth is removed.

The extracted wisdom tooth is placed in a sterile container and transported under cold conditions to a laboratory. There, specialists extract the pulp tissue and typically freeze the stem cells within a day to preserve their viability.

Proponents note that banking one’s own DPSCs eliminates concerns about immune rejection later, and the upfront cost (comparable to cord‑blood banking) could pay off if personalized therapies are needed decades down the line.

Clinics partner with oral surgeons to harvest molars that would otherwise be discarded, turning “trash” into a long‑term biological asset. Early experiments hint at a wide range of potential therapies.

For example, cardiologists have tested injections of dental‑pulp cell secretions in rodents with heart failure, and observed improved cardiac function – suggesting that a patient’s own wisdom‑tooth cells might one day help mend a damaged heart.

In neurological studies, DPSC transplants into Alzheimer’s‑model mice produced measurable improvements in memory and brain pathology.

It can generate dopamine‑producing neurons in culture, and rodent models of Parkinson’s disease showed motor improvements with dental stem cell therapy.

DPSCs appear to secrete a cocktail of growth factors that protect nerves, reduce inflammation and even help clear toxic proteins in the brain. Outside the nervous system, laboratories report that dental pulp cells readily become osteoblast‑like and build bone in 3D scaffolds, making them promising for filling bone defects.

More Work Is Needed to Prove Safety and Efficacy

As the evidence grows, investigators are planning clinical trials of dental pulp therapies. Early stem‑cell implants (using embryonic stem cells) in Parkinson’s patients have already demonstrated that new dopamine neurons can survive and function in humans. Using DPSCs instead could avoid ethical controversies and reduce immune risk.

However, experts caution that more work is needed. Transplanted cells must be shown safe (without forming tumors) and effective in people. Scientists at universities and institutes worldwide – for example at the University of the Basque Country in Spain – continue refining protocols to turn tooth pulp into therapy. “These are easily accessible human stem cells for nerve tissue engineering,” researchers note.

They argue that routinely preserving wisdom teeth now could create a personalized “biobank” of one’s own stem cells, offering future regenerative treatments without the wait for a perfect donor match. Wisdom teeth may have been viewed as nuisances, but modern research is recasting them as biological treasure.

Before tossing those extracted molars, patients might consider the hidden value inside. In the coming years, therapies for bone injuries, neurological diseases or heart disease may indeed spring from the “medical gold” locked in wisdom tooth pulp.

[Source: 1,2]

The post “Medical Gold” From Extracted Wisdom Teeth Are Being Used to Treat a Range of Diseases appeared first on Medical Journal Daily.